CME/CE

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This three-part panel series explores how emerging evidence from the CONFIDENCE trial is shaping the future of cardio-kidney-metabolic (CKM) care. In Chapter 1, the experts discuss the additive benefits and safety of combining a nonsteroidal MRA and an SGLT2 inhibitor. Chapter 2 focuses on patient selection and individualized strategies for initiating combination therapy. Chapter 3 shifts to real-world implementation, highlighting multidisciplinary collaboration and strategies to improve adherence and continuity of care. Together, this series provides a roadmap to optimize outcomes in patients with CKD and T2D.

In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer. By illustrating the use of antibody-drug conjugates in HER2-expressing disease, participants will gain insights into optimal evidence-based treatment selection based upon HER2 expression.

Our experts, Drs. Robert Motzer and Elizabeth Plimack, discuss first-line treatment strategies for advanced renal cell carcinoma in a community clinic setting. Drawing from pivotal clinical trials and guideline recommendations, they highlight how to personalize therapy based on IMDC risk stratification and patient characteristics. Practical decision-making in both intermediate- and poor-risk disease is examined through 2 detailed patient cases, with an emphasis on outcomes, therapy sequencing, and real-world considerations. The discussion also addresses immune-related and TKI-associated adverse events and outlines monitoring and management strategies that support patient safety and treatment continuity. Tune in for expert reflections on integrating evolving data into daily oncology practice.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.